Vestal Point Capital, LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Vestal Point Capital, LP reported 60 stock positions worth $1.3 billion. Its top holding was Jazz Pharmaceuticals (JAZZ) at 11.9% of the portfolio, followed by Cytokinetics (CYTK, 8.4%) and Ascendis Pharma A/S (ASND, 7.6%). Compared with Q1 2024, it opened 22 new positions, sold out of 20, added to 28 and reduced 5. The biggest buy was Ultragenyx Pharmaceutical (RARE, shares +1536%) and the biggest sale an exit from Neurocrine Biosciences (NBIX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001974915
- Portfolio Value
- $1.3B (Q2 2024)
- SEC Filing
- 0001974915-24-000006 ↗ filed Aug 14, 2024
Holdings Value
Holdings 60 stocks · $1.3B
| JAZZ Jazz Pharmaceuticals PLC | 11.94% | 1,500,000 | $160.1M | Add +36.4% |
| CYTK Cytokinetics Inc. | 8.38% | 2,075,000 | $112.4M | Reduce -3.5% |
| ASND Ascendis Pharma A/S | 7.63% | 750,000 | $102.3M | Add +42.9% |
| RARE Ultragenyx Pharmaceutical Inc. | 5.52% | 1,800,000 | $74.0M | Add +1536.4% |
| GMED Globus Medical Inc. Class A | 4.60% | 900,000 | $61.6M | Reduce -10.0% |
| INSM Insmed Inc. | 3.75% | 750,000 | $50.3M | No change |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 3.72% | 350,000 | $49.9M | Add +7.7% |
| SLNO Soleno Therapeutics Inc. | 3.65% | 1,200,000 | $49.0M | Reduce -4.0% |
| EXAS Exact Sciences Corp. | 2.91% | 925,000 | $39.1M | Add +825.0% |
| ACLX Arcellx Inc. | 2.78% | 675,000 | $37.3M | Add +575.0% |
| IMTX Immatics NV | 2.38% | 2,750,000 | $32.0M | Add +129.2% |
| JANX Janux Therapeutics Inc. | 2.26% | 725,000 | $30.4M | New |
| ATXS Astria Therapeutics Inc. | 2.21% | 3,250,000 | $29.6M | Add +195.4% |
| KALV Kalvista Pharmaceuticals Inc. | 2.02% | 2,300,000 | $27.1M | Add +251.2% |
| SVRA Savara Inc. | 1.95% | 6,490,000 | $26.2M | New |
| ITOS Iteos Therapeutics Inc. | 1.94% | 1,750,000 | $26.0M | New |
| APLT Applied Therapeutics Inc. | 1.89% | 5,430,000 | $25.4M | Add +6.3% |
| AXSM Axsome Therapeutics Inc. | 1.80% | 300,000 | $24.1M | New |
| GPCR Structure Therapeutics Inc. | 1.64% | 560,000 | $22.0M | New |
| LQDA Liquidia Corp. | 1.64% | 1,830,000 | $22.0M | Reduce -8.5% |
| ALXO Alx Oncology Holdings Inc. | 1.62% | 3,600,000 | $21.7M | Add +37.9% |
| QURE Uniqure NV | 1.59% | 4,750,000 | $21.3M | Add +0.5% |
| BMY Bristol-Myers Squibb Co. | 1.55% | 500,000 | $20.8M | New |
| XENE Xenon Pharmaceuticals Inc. | 1.53% | 525,000 | $20.5M | Add +31.3% |
| PRAX Praxis Precision Medicines I | 1.36% | 440,000 | $18.2M | Add +109.5% |
| DAWN Day One Biopharmaceuticals I | 1.28% | 1,250,000 | $17.2M | New |
| NARI Inari Medical Inc. | 1.26% | 350,000 | $16.9M | Reduce -56.3% |
| DNTH Dianthus Therapeutics Inc. | 1.16% | 600,000 | $15.5M | Add +31.9% |
| SLDB Solid Biosciences Inc. | 1.13% | 2,665,000 | $15.1M | Add +157.5% |
| LXEO Lexeo Therapeutics Inc. | 1.00% | 840,000 | $13.5M | Add +380.0% |
| APLS Apellis Pharmaceuticals Inc. | 0.96% | 335,000 | $12.9M | Add +48.9% |
| IMNM Immunome Inc. | 0.90% | 1,000,000 | $12.1M | New |
| DNLI Denali Therapeutics Inc. | 0.87% | 500,000 | $11.6M | New |
| NRIX Nurix Therapeutics Inc. | 0.78% | 500,000 | $10.4M | New |
| BDTX Black Diamond Therapeutics I | 0.73% | 2,100,000 | $9.8M | New |
| BNTX Biontech SE-ADR | 0.60% | 100,000 | $8.0M | New |
| INSP Inspire Medical Systems Inc. | 0.60% | 60,000 | $8.0M | New |
| PCRX Pacira Biosciences Inc. | 0.60% | 280,000 | $8.0M | Add +250.0% |
| DYN Dyne Therapeutics Inc. | 0.59% | 225,000 | $7.9M | New |
| FULC Fulcrum Therapeutics Inc. | 0.54% | 1,160,000 | $7.2M | Add +66.9% |
| ANRO Alto Neuroscience Inc. | 0.49% | 620,000 | $6.6M | Add +148.0% |
| FATE Fate Therapeutics Inc. | 0.49% | 2,000,000 | $6.6M | Add +150.0% |
| ALLO Allogene Therapeutics Inc. | 0.38% | 2,200,000 | $5.1M | Add +63.0% |
| PASG Passage Bio Inc. | 0.36% | 6,052,000 | $4.8M | Add +34.5% |
| VYGR Voyager Therapeutics Inc. | 0.35% | 600,000 | $4.7M | No change |
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 0.33% | 180,000 | $4.5M | Add +38.5% |
| ZYME Zymeworks Inc. | 0.28% | 440,000 | $3.7M | New |
| RLMD Relmada Therapeutics Inc. | 0.27% | 1,200,000 | $3.6M | No change |
| MGNX Macrogenics Inc. | 0.25% | 800,000 | $3.4M | Add +10.3% |
| GLUE Monte Rosa Therapeutics Inc. | 0.25% | 890,000 | $3.3M | New |
| VTYX Ventyx Biosciences Inc. | 0.23% | 1,315,000 | $3.0M | New |
| PTCT PTC Therapeutics Inc. | 0.21% | 90,000 | $2.8M | New |
| VERV Verve Therapeutics Inc. | 0.18% | 500,000 | $2.4M | New |
| IOVA Iovance Biotherapeutics Inc. | 0.18% | 300,000 | $2.4M | New |
| PRME Prime Medicine Inc. | 0.17% | 450,000 | $2.3M | Add +25.0% |
| CMRX Chimerix Inc. | 0.09% | 1,400,000 | $1.2M | No change |
| ACHL Achilles Therapeutics PL-ADR | 0.09% | 1,500,000 | $1.2M | No change |
| ATRA Atara Biotherapeutics Inc. | 0.07% | 112,000 | $952K | New |
| RENEO PHARMACEUTICALS INC | 0.06% | 545,000 | $823K | Add +84.5% |
| NAMS Newamsterdam Pharma Co. NV | 0.04% | 25,000 | $480K | New |
Portfolio Sells Q1 2024 → Q2 2024
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −8.10 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −4.33 |
| CYTK Cytokinetics Inc. | Reduce -3.5% | 8.38% | −4.08 |
| AZN Astrazeneca PLC-Spons ADR | Sold out | 0.00% | −2.24 |
| NARI Inari Medical Inc. | Reduce -56.3% | 1.26% | −1.92 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −1.63 |
| TGTX TG Therapeutics Inc. | Sold out | 0.00% | −1.32 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −1.26 |
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −1.15 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −1.07 |
| INCY Incyte Corp. | Sold out | 0.00% | −0.94 |
| LQDA Liquidia Corp. | Reduce -8.5% | 1.64% | −0.80 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.79 |
| SLNO Soleno Therapeutics Inc. | Reduce -4.0% | 3.65% | −0.77 |
| SWAV Shockwave Medical Inc. | Sold out | 0.00% | −0.67 |
| KRYS Krystal Biotech Inc. | Sold out | 0.00% | −0.66 |
| GERN Geron Corp. | Sold out | 0.00% | −0.60 |
| VKTX Viking Therapeutics Inc. | Sold out | 0.00% | −0.51 |
| BIO Bio-Rad Laboratories-A | Sold out | 0.00% | −0.43 |
| LYRA Lyra Therapeutics Inc. | Sold out | 0.00% | −0.41 |
| NVAX Novavax Inc. | Sold out | 0.00% | −0.20 |
| ATRA Atara Biotherapeutics Inc. | Sold out | 0.00% | −0.16 |
| AFMDQ Affimed NV | Sold out | 0.00% | −0.02 |
| LYEL Lyell Immunopharma Inc. | Sold out | 0.00% | −0.02 |
| GMED Globus Medical Inc. Class A | Reduce -10.0% | 4.60% | +0.16 |
Portfolio Buys Q1 2024 → Q2 2024
| RARE Ultragenyx Pharmaceutical Inc. | Add +1536.4% | 5.52% | +5.09 |
| EXAS Exact Sciences Corp. | Add +825.0% | 2.91% | +2.34 |
| JANX Janux Therapeutics Inc. | New | 2.26% | +2.26 |
| ACLX Arcellx Inc. | Add +575.0% | 2.78% | +2.20 |
| SVRA Savara Inc. | New | 1.95% | +1.95 |
| ITOS Iteos Therapeutics Inc. | New | 1.94% | +1.94 |
| AXSM Axsome Therapeutics Inc. | New | 1.80% | +1.80 |
| GPCR Structure Therapeutics Inc. | New | 1.64% | +1.64 |
| BMY Bristol-Myers Squibb Co. | New | 1.55% | +1.55 |
| KALV Kalvista Pharmaceuticals Inc. | Add +251.2% | 2.02% | +1.38 |
| IMTX Immatics NV | Add +129.2% | 2.38% | +1.34 |
| DAWN Day One Biopharmaceuticals I | New | 1.28% | +1.28 |
| ASND Ascendis Pharma A/S | Add +42.9% | 7.63% | +1.06 |
| JAZZ Jazz Pharmaceuticals PLC | Add +36.4% | 11.94% | +0.98 |
| ATXS Astria Therapeutics Inc. | Add +195.4% | 2.21% | +0.92 |
| IMNM Immunome Inc. | New | 0.90% | +0.90 |
| DNLI Denali Therapeutics Inc. | New | 0.87% | +0.87 |
| NRIX Nurix Therapeutics Inc. | New | 0.78% | +0.78 |
| LXEO Lexeo Therapeutics Inc. | Add +380.0% | 1.00% | +0.78 |
| BDTX Black Diamond Therapeutics I | New | 0.73% | +0.73 |
| BNTX Biontech SE-ADR | New | 0.60% | +0.60 |
| INSP Inspire Medical Systems Inc. | New | 0.60% | +0.60 |
| DYN Dyne Therapeutics Inc. | New | 0.59% | +0.59 |
| PCRX Pacira Biosciences Inc. | Add +250.0% | 0.60% | +0.40 |
| PRAX Praxis Precision Medicines I | Add +109.5% | 1.36% | +0.30 |
| ZYME Zymeworks Inc. | New | 0.28% | +0.28 |
| GLUE Monte Rosa Therapeutics Inc. | New | 0.25% | +0.25 |
| VTYX Ventyx Biosciences Inc. | New | 0.23% | +0.23 |
| PTCT PTC Therapeutics Inc. | New | 0.21% | +0.21 |
| VERV Verve Therapeutics Inc. | New | 0.18% | +0.18 |
| IOVA Iovance Biotherapeutics Inc. | New | 0.18% | +0.18 |
| ANRO Alto Neuroscience Inc. | Add +148.0% | 0.49% | +0.18 |
| XENE Xenon Pharmaceuticals Inc. | Add +31.3% | 1.53% | +0.10 |
| ATRA Atara Biotherapeutics Inc. | New | 0.07% | +0.07 |
| NAMS Newamsterdam Pharma Co. NV | New | 0.04% | +0.04 |
| DNTH Dianthus Therapeutics Inc. | Add +31.9% | 1.16% | +0.03 |
| RENEO PHARMACEUTICALS INC | Add +84.5% | 0.06% | +0.02 |
| FATE Fate Therapeutics Inc. | Add +150.0% | 0.49% | +0.00 |
| FULC Fulcrum Therapeutics Inc. | Add +66.9% | 0.54% | −0.01 |
| SLDB Solid Biosciences Inc. | Add +157.5% | 1.13% | −0.01 |
| LKFT Lakefront Biotherapeutic-ADR | Add +38.5% | 0.33% | −0.01 |
| PRME Prime Medicine Inc. | Add +25.0% | 0.17% | −0.04 |
| ALLO Allogene Therapeutics Inc. | Add +63.0% | 0.38% | −0.12 |
| APLS Apellis Pharmaceuticals Inc. | Add +48.9% | 0.96% | −0.14 |
| PASG Passage Bio Inc. | Add +34.5% | 0.36% | −0.14 |
| QURE Uniqure NV | Add +0.5% | 1.59% | −0.45 |
| ONC Beone Medicines Ltd.-ADR | Add +7.7% | 3.72% | −0.48 |
| MGNX Macrogenics Inc. | Add +10.3% | 0.25% | −0.63 |
| ALXO Alx Oncology Holdings Inc. | Add +37.9% | 1.62% | −0.79 |
| APLT Applied Therapeutics Inc. | Add +6.3% | 1.89% | −0.98 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $4.3B | BMRN, NBIX, ABVX, UTHR, ELVN |
| Q1 2026 | 90 | $3.6B | RVMD, BMRN, ABVX, NBIX, ARWR |
| Q4 2025 | 75 | $2.7B | ABVX, ACLX, TERN, BMRN, GMED |
| Q3 2025 | 80 | $2.2B | ASND, ACLX, NUVL, ABVX, ALC |
| Q2 2025 | 72 | $1.9B | ACLX, JAZZ, CYTK, NUVL, VERA |
| Q1 2025 | 63 | $1.4B | ACLX, CYTK, INSM, NUVL, VERA |
| Q4 2024 | 73 | $1.7B | JAZZ, CYTK, MRK, ASND, RARE |
| Q3 2024 | 67 | $1.3B | INSM, JAZZ, CYTK, NARI, ACLX |
| Q2 2024 | 60 | $1.3B | JAZZ, CYTK, ASND, RARE, GMED |
| Q1 2024 | 58 | $1.2B | CYTK, JAZZ, NBIX, ASND, GMED |